CS
GTHX

Credit Suisse’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Credit Suisse’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-38,602
Closed -$103K – 3286
2023
Q1 		$103K Buy
38,602
+4,013
+12% +$19.3K ﹤0.01% 3204
2022
Q4 		$188K Buy
+34,589
New +$290K ﹤0.01% 3201
2022
Q3 		– Sell
-1
Closed – – 4376
2022
Q2 		$0 Sell
1
-22,128
-100% -$123K ﹤0.01% 4418
2022
Q1 		$168K Buy
22,129
+744
+3% +$7.06K ﹤0.01% 3412
2021
Q4 		$218K Sell
21,385
-6,027
-22% -$76.8K ﹤0.01% 4243
2021
Q3 		$367K Buy
27,412
+7,034
+35% +$115K ﹤0.01% 3999
2021
Q2 		$448K Sell
20,378
-2,644
-11% -$58.7K ﹤0.01% 3908
2021
Q1 		$554K Sell
23,022
-48,818
-68% -$1.13M ﹤0.01% 3703
2020
Q4 		$1.29M Sell
71,840
-15,820
-18% -$236K ﹤0.01% 3141
2020
Q3 		$1.01M Buy
87,660
+42,057
+92% +$694K ﹤0.01% 2924
2020
Q2 		$1.11M Buy
45,603
+23,159
+103% +$383K ﹤0.01% 2819
2020
Q1 		$248K Sell
22,444
-5,613
-20% -$105K ﹤0.01% 3538
2019
Q4 		$742K Buy
28,057
+3,108
+12% +$72.7K ﹤0.01% 3325
2019
Q3 		$568K Buy
24,949
+7,584
+44% +$239K ﹤0.01% 3365
2019
Q2 		$532K Buy
17,365
+2,290
+15% +$48.2K ﹤0.01% 3362
2019
Q1 		$250K Buy
15,075
+3,594
+31% +$68.2K ﹤0.01% 3687
2018
Q4 		$219K Sell
11,481
-7,708
-40% -$289K ﹤0.01% 3644
2018
Q3 		$1M Buy
19,189
+2,071
+12% +$113K ﹤0.01% 2872
2018
Q2 		$744K Buy
17,118
+9,244
+117% +$396K ﹤0.01% 3216
2018
Q1 		$292K Buy
+7,874
New +$210K ﹤0.01% 3584

Other funds holding GTHX

Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Credit Suisse's GTHX Position: Q2 2023 in Review

Credit Suisse sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q2 2023, closing a stake of 38,602 shares — an estimated $103K sold.

Credit Suisse first reported a position in GTHX in Q1 2018 and held it in 20 quarters. The position peaked at $1.29M in Q4 2020. 80 funds tracked by Wall St. Rank hold GTHX as of Q2 2023.

  • Credit Suisse reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Credit Suisse sold 38,602 G1 Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $103K.
  • Credit Suisse first reported a position in G1 Therapeutics, Inc. Common Stock in Q1 2018 and held it in 20 quarters.
  • Credit Suisse's G1 Therapeutics, Inc. Common Stock position peaked at $1.29M in Q4 2020.
  • 80 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Credit Suisse's 13F filing for Q2 2023, filed 11 Aug 2023.